In a nutshell This study examined if there was a difference in patients with breast cancer first treated with chemotherapy that had a wide or narrow margin of healthy tissue removed during surgery. The results showed that the outcomes were similar regardless of how much healthy tissue was removed. Some background Traditionally, mastectomy (the...
Read MoreConfined or spread disease-Spread to regional lymph nodes Posts on Medivizor
Long-term outcomes of pertuzumab added to trastuzumab and docetaxel treatment for patients with advanced HER2-positive breast cancer
In a nutshell This study looked at whether pertuzumab (Perjeta) benefits patients with metastatic HER2-positive breast cancer when added to trastuzumab (Herceptin) and docetaxel (Taxotere) treatment. They found that adding pertuzumab improved long-term patient outcomes. Some background Breast cancer can now be tested for some of the signals involved...
Read MoreAtezolizumab and nab-paclitaxel for unresectable advanced triple-negative breast cancer
In a nutshell This study aimed to investigate the effectiveness and safety of atezolizumab plus nab-paclitaxel in unresectable, locally advanced or metastatic triple-negative breast cancer. This study concluded that this combination had a benefit in patients with PD-L1 immune cell positive...
Read MorePalbociclib and exemestane versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer
In a nutshell This study aimed to compare the safety and effectiveness of palbociclib and endocrine therapy to capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. This study concluded that palbociclib and endocrine therapy is more effective than...
Read MoreReview of treatment options for patients with advanced melanoma
In a nutshell This article reviewed treatment options for patients with advanced melanoma. Some background Treatment for melanoma depends on several factors, including the disease stage. Advanced melanoma is diagnosed when cancer can be detected outside of the original tumor. This makes treatment difficult. Currently, there...
Read MoreReviewing treatment recommendations for patients with melanoma
In a nutshell This article reviewed different treatment options for patients with melanoma. Some background Melanoma is one of the most common cancers worldwide. Treatment options for patients with melanoma depend on how extensive it is. Melanoma that remains in its original site in the skin is called localized disease. It can also...
Read MoreComparing 6- and 12-month trastuzumab treatment after surgery for early breast cancer
In a nutshell This study aimed to compare the outcomes for patients with early breast cancer who received 6- or 12-months trastuzumab after surgery. This study concluded that the standard duration of trastuzumab after surgery should remain 12 months. Some background Trastuzumab (Herceptin) is a targeted...
Read MoreComparing endocrine treatment versus chemotherapy for metastatic breast cancer
In a nutshell This study compared hormone therapy and chemotherapy for the treatment of metastatic (cancer that has spread) breast cancer. The authors concluded that hormone therapy plus targeted therapy is better than chemotherapy for patients with metastatic breast cancer. Some background Different types of breast cancer have different receptors....
Read MoreEnding trastuzumab treatment in patients with HER2-positive metastatic breast cancer who are in radiological complete remission
In a nutshell This study aimed to investigate the effect of stopping trastuzumab treatment in patients with HER2-positive metastatic breast cancer with radiological complete remission. This study concluded that trastuzumab may be safely stopped in selected patients with radiological complete...
Read MoreLooking for patients with advanced triple negative breast cancer to test a new treatment
In a nutshell This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with solid tumors such as triple-negative breast cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US. The...
Read MoreLooking for patients with advanced melanoma to test a combination of antibody and enzyme drugs
In a nutshell This trial is examining if adding antibody drug rituximab (Rituxan) and enzyme drug hyaluronidase human (Hycela) can increase the effectiveness of the standard treatment for melanoma. The main outcomes of this trial will be to examine the side effects experienced by patients and tumor response. This study is recruiting in...
Read MoreSearching for patients with advanced triple-negative breast cancer to test a new combination treatment
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...
Read More